MTOR and cancer: In addition, ISLA reduced the levels of pro-angiogenic factors such as MMP-9, PlGF, and VEGF in HT1080 CM via suppression of the HIF-1α/Akt/mTOR pathway, supporting the anti-angiogenic activity of ISLA in cancer cells (Figure 5).